Stock A096530 SEEGENE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Seegene, Inc. Stock

Equities

A096530

KR7096530001

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 2024-12-11 		5-day change 1st Jan Change
23,100.00 KRW +1.54% Intraday chart for Seegene, Inc. -1.07% +0.87%
Nov. 14 Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
Oct. 08 Seegene, Inc. and Werfen, S.A. Finalize Partnership Agreement on Technology-Sharing Initiative CI

Valuation: Seegene, Inc.

Capitalization 1,067B 747M 712M 660M 586M 1.06B 63.3B 1.17B 8.2B 3.04B 26.03B 2.8B 2.74B 114B P/E ratio 2024 *
38.3x
P/E ratio 2025 * 33x
Enterprise value 1,067B 747M 712M 660M 586M 1.06B 63.3B 1.17B 8.2B 3.04B 26.03B 2.8B 2.74B 114B EV / Sales 2024 *
2.61x
EV / Sales 2025 * 2.29x
Free-Float
58.47%
Yield 2024 *
3.46%
Yield 2025 * 3.46%
More valuation ratios * Estimated data

Chart: Seegene, Inc.

Dynamic Chart

Latest news: Seegene, Inc.

Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 13 CI
Seegene, Inc. and Werfen, S.A. Finalize Partnership Agreement on Technology-Sharing Initiative Oct. 08 CI
Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index Sep. 22 CI
Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration Aug. 26 CI
Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Aug. 14 CI
Seegene, Inc.'s Equity Buyback Plan Extended till July 14, 2025. Jul. 11 CI
Seegene, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 May. 15 CI
Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 Mar. 14 CI
Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases Jan. 24 CI
Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy; Expanded Collaboration Aims To Improve Syndromic Infectious Disease Testing Dec. 14 MT
Microbix Brief: Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy Dec. 14 MT
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 14 CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on July 13, 2023. 23-10-13 CI
More news

Press Releases: Seegene, Inc.

/C O R R E C T I O N -- Seegene Inc./ Oct. 28 AQ
Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative Oct. 24 AQ
Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative Oct. 08 AQ
Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1 Sep. 09 AQ
Seegene and Springer Nature Launch Nature Awards MDx Impact Grants, to Innovate Syndromic PCR Diagnostic Assays Sep. 03 AQ
More press releases

News in other languages: Seegene, Inc.

++ Analysen des Tages von Dow Jones Newswires (12.02.2021) +++ 21-02-12
Seegene : ANALYSE/Südkoreas Gewinnabschöpfungsidee als internationales Vorbild? 21-02-12
More news

Quotes and Performance

1 day+1.54%
1 week-1.07%
Current month-2.74%
3 months-9.23%
6 months+13.51%
Current year+0.87%
More quotes

Course Extremes

1 week
21 250.00
Extreme 21250
23 150.00
1 month
21 250.00
Extreme 21250
24 500.00
Current year
19 500.00
Extreme 19500
35 950.00
1 year
19 500.00
Extreme 19500
35 950.00
3 years
19 040.00
Extreme 19040
73 300.00
5 years
13 550.00
Extreme 13550
161 100.00
10 years
7 225.00
Extreme 7225
161 100.00
More quotes

Managers and Directors: Seegene, Inc.

Director TitleAgeSince
Jong-Yoon Chun CEO
 Chief Executive Officer 67 2010-09-16
Ho Lee PSD
 President 65 -
Min-Chul Lee PSD
 President 70 -
Manager TitleAgeSince
Jong-Yoon Chun BRD
 Director/Board Member 67 2011-06-30
Kyung-Jun Chun CHM
 Chairman 77 -
Hong-Il Yoon BRD
 Director/Board Member 62 2011-06-30
More insiders

ETFs: Seegene, Inc.

Name Weight AuM 1st Jan change Investor Rating
GOLDMAN SACHS ACTIVEBETA EMERGING MARKETS EQUITY UCITS ETF - ACC - USD ETF Goldman Sachs ActiveBeta Emerging Markets Equity UCITS ETF - Acc - USD
0.10% 12 M€ +9.94%
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
0.10% 2 M€ -.--%
BMO MSCI INNOVATION INDEX ETF - CAD ETF BMO MSCI Innovation Index ETF - CAD
0.03% 7 M€ -.--% -
More ETFs: Seegene, Inc.

Bio Diagnostics & Testing

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
SEEGENE, INC. Stock Seegene, Inc.
+1.54%-1.07%-2.33%-64.19%735M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
+2.57%-1.53%-2.92%-20.35%11.4B
VERACYTE, INC. Stock Veracyte, Inc.
+1.23%-1.32%+69.89%+10.94%3.33B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
-0.12%-1.72%+37.28%-53.55%2.62B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
+0.21%+5.22%-6.37%-48.37%2.5B
CAREDX, INC Stock CareDx, Inc
+0.46%-6.71%+150.57%-43.72%1.29B
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-4.92%+3.91%+39.00%-76.10%990M
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
-2.70%+6.56%+12.04%-85.38%841M
VIMTA LABS LIMITED Stock Vimta Labs Limited
-0.59%-1.86%+113.76%+121.61%242M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+0.66%+0.77%-13.11% - 206M
Average -0.17%+0.50%+39.78%-28.79% 2.41B
Weighted average by Cap. +1.17%-0.33%+22.67%-28.31%
See all sector performances

Financials

2024 *2025 *
Net sales 409B 286M 273M 253M 224M 404M 24.23B 449M 3.14B 1.16B 9.97B 1.07B 1.05B 43.58B 466B 326M 311M 288M 256M 461M 27.65B 512M 3.58B 1.33B 11.37B 1.23B 1.2B 49.73B
Net income 31.5B 22.03M 21.01M 19.48M 17.28M 31.15M 1.87B 34.6M 242M 89.62M 768M 82.76M 80.93M 3.36B 36.6B 25.6M 24.41M 22.64M 20.08M 36.19M 2.17B 40.21M 281M 104M 892M 96.16M 94.03M 3.9B
Net Debt - -
More financial data * Estimated data

Company Profile

Logo Seegene, Inc.
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
Employees
63
Sector
Biotechnology & Medical Research
Calendar
2025-02-12 - Q4 2024 Earnings Release (Projected)
More about the company

Quotes

Date Price Change Volume
24-12-11 23,100.00 ₩ +1.54% 162,448
24-12-10 22,750.00 ₩ +6.81% 200,905
24-12-09 21,300.00 ₩ -6.99% 390,880
24-12-06 22,900.00 ₩ +1.10% 350,235
24-12-05 22,650.00 ₩ -3.00% 269,732

End-of-day quote Korea S.E., December 10, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart SEEGENE-INC More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
C+
surperformance-ratings-light-chart SEEGENE-INCMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
23,100.00KRW
Average target price
38,000.00KRW
Spread / Average Target
+64.50%
Consensus
Profit revisions
estimates-change-chart SEEGENE-INC Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SEEGENE-INC Company calendar
  1. Stock Market
  2. Equities
  3. A096530 Stock